MDXG News and Press, MiMedx Group Inc From 08/26/22

The Cato T. Laurencin Regenerative Engineering Founders’ Award Promotes Advancement of Scientific Leadership and Research in the Field of Regenerative Engineering MARIETTA, Ga., Aug. 26, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or t...

MARIETTA, Ga., Aug. 04, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that senior management will present at the Canaccord Genuity 42 nd Annual Growth Co...

MiMedx Group, Inc. (MDXG) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Jack Howarth – Senior Vice President-Investor Relations Tim Wright – Chief Executive Officer Pete Carlson – Chief Financial Officer ...

MiMedx Group press release ( NASDAQ: MDXG ): Q2 GAAP EPS of -$0.11 misses by $0.04 . Revenue of $66.88M (-1.9% Y/Y) beats by $1.81M . The company is maintaining its outlook for FY2022, as disclosed in its earnings release for the year ended December 31, 2021, i...

Second Quarter Net Sales of $66.9 Million Reflects Double-Digit Revenue Increase for the Fourth Consecutive Quarter in the Company's Continuing Portfolio of Products Achieves Strong Year-Over-Year Revenue Growth in Key Focus Area of Surgical Recovery Company Reaffirms 20...

Scientific Advisory Board Adds Multi-disciplinary Clinical and Scientific Expertise to Support Acceleration of the Company’s mdHACM Placental Biologics Pipeline MARIETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the &...

MARIETTA, Ga., July 20, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that it will report operating and financial results for the second quarter ended June 3...

Proven Biotech Executive Brings Versatile Leadership Experience MARIETTA, Ga., July 18, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced the addition ...

MiMedx (NASDAQ:MDXG) has entered into an agreement with contract research organization Nordic Bioscience Clinical Development to run registrational trials for its placental biological treatment for knee osteoarthritis. Nordic Bioscience specializes in osteoarthritis trials. MiMedx is developi...

Image Analysis Group to Provide Imaging Strategy and Advanced Imaging Analytics in Support of MIMEDX’s Knee Osteoarthritis Clinical Trial Program MARIETTA, Ga., June 15, 2022 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Compan...